TY - JOUR
T1 - Imaging of angiogenesis in cardiology
AU - Higuchi, Takahiro
AU - Wester, Hans Juergen
AU - Schwaiger, Markus
N1 - Funding Information:
Acknowledgements The authors thank Ura Frenklah, M.D. for his excellent editorial help. The work relating to 18F-gRGD was in part supported by the Deutsche Forschungsgemeinschaft and a Bristol-Myers Squibb unrestricted research grant.
PY - 2007/6
Y1 - 2007/6
N2 - In the past decade, there have been major improvements in our understanding of angiogenesis at the genetic, molecular and cellular levels. Concentrated efforts in this area have led to new therapeutic approaches to ischaemic heart disease using angiogenic factors, gene therapy and progenitor cells. Despite very promising experimental results in animal studies, large clinical trials have failed to confirm the results in patients with coronary artery disease. Important questions such as selection of growth factors and donor cells, as well as the timing, dose and route of administration, have been raised and need to be answered. Molecular imaging approaches which may provide specific markers of the angiogenic process (e.g. integrin expression in endothelial cells) have been introduced and are expected to address some of these questions. Although few clinical imaging results are currently available, animal studies suggest the potential role of molecular imaging for characterisation of the angiogenetic process in vivo and for the monitoring of therapeutic effects.
AB - In the past decade, there have been major improvements in our understanding of angiogenesis at the genetic, molecular and cellular levels. Concentrated efforts in this area have led to new therapeutic approaches to ischaemic heart disease using angiogenic factors, gene therapy and progenitor cells. Despite very promising experimental results in animal studies, large clinical trials have failed to confirm the results in patients with coronary artery disease. Important questions such as selection of growth factors and donor cells, as well as the timing, dose and route of administration, have been raised and need to be answered. Molecular imaging approaches which may provide specific markers of the angiogenic process (e.g. integrin expression in endothelial cells) have been introduced and are expected to address some of these questions. Although few clinical imaging results are currently available, animal studies suggest the potential role of molecular imaging for characterisation of the angiogenetic process in vivo and for the monitoring of therapeutic effects.
KW - Angiogenesis
KW - Molecular imaging
KW - PET
KW - RGD
UR - http://www.scopus.com/inward/record.url?scp=34250764738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250764738&partnerID=8YFLogxK
U2 - 10.1007/s00259-007-0436-z
DO - 10.1007/s00259-007-0436-z
M3 - Review article
C2 - 17479264
AN - SCOPUS:34250764738
SN - 1619-7070
VL - 34
SP - S9-S19
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 1 SUPPL.
ER -